Australia: Drug In Focus: Donepezil

Last Updated: 11 October 2010
Article by Kevin Wang

Donepezil (Aricept®), an anti-dementia/anti-Alzheimer's treatment developed by Eisai and co-marketed by Pfizer, will lose key patent protection in some major territories in the near future. Currently, Aricept® is the world's best selling anti-Alzheimer's drug and generated sales of 303 billion Japanese Yen for Eisai and US$432 million for Pfizer in 2009. Based on the information contained in GenericsWeb's Donepezil Pipeline Selector report, this month's Drug In Focus will analyse the patent landscape surrounding the Aricept® product with a view of launching generic equivalents.

Table 1: Donepezil General Information

According to the General Information (Table 1), Donepezil is available as the hydrochloride salt in film coated tablet and orally disintegrating tablet (ODT) dosage forms in 5mg and 10mg dosing strengths and is indicated for the treatment of Alzheimer's type dementia.

Six different patent families have been identified by Key Patent Information (KPI, Table 2) as being important in protecting the innovator product and potentially in preventing generic versions of Donepezil from entering the market. All of these key patent families were filed by the innovator, Eisai. It can be easily seen from the Data Exclusivity section of the KPI that data exclusivity has expired in all major territories and does not constrain approval of generic versions of Donepezil.

Table 2: Key Patent Information

Donepezil Key Patent and Data Exclusivity Information

INN Priority Data Patentee Patent Title
DONEPEZIL JP15505887A (22/06/1987) Eisai Co Ltd [JP] 1,4-substituted piperidines as acetylcholinesterase inhibitors and their use for the treatment of alzheimer's disease
DONEPEZIL JP14629396A (07/06/1996) Eisai Co Ltd [JP] Stable polymorphs of donepezil (1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine) hydrochloride and process for production
DONEPEZIL JP33616597A (05/12/1997) Eisai Co Ltd [JP] Donepezil polycrystals and process for producing the same
DONEPEZIL JP9901686W (31/03/1999) Eisai Co Ltd [JP] Stabilized compositions containing nootropic drugs
DONEPEZIL JP5617600A (01/03/2000) Eisai R&D Man Co Ltd [JP] Rapidly disintegrable tablet containing polyvinyl alcohol
DONEPEZIL JP7856897A (28/03/1997) Eisai R&D Man Co Ltd [JP] Oral pharmaceutical preparations decreased in bitterness by masking

The members of the first patent family of the KPI, which protect the Donepezil compound per se, have been granted Supplementary Protection Certificates (SPCs) in most European countries and will expire in February 2012. A patent term extension has also been granted in Australia, extending the expiry until March 2013. In the US, the patent has been granted a s156 term extension yet will expire in November 2010. Despite a lack of patent extension scheme in Canada, the two Canadian equivalents will be in force until end of 2013 and 2015 as they benefit from the longer term of 20 years from application date or 17 years from grant date.

The patents in the second and third families identified in the KPI claim crystalline polymorphic forms of Donepezil hydrochloride and Donepezil free compound. In the second family, the patent members will be in force until 2016 in the US and 2017 in Australia, Canada and Europe, however all the patents in the third family will expire in 2018. Since the commercial product contains the hydrochloride salt, it would seem unlikely that a patent protecting a crystalline form of the free compound could protect those products. However, US6245911 is listed in the FDA Orange Book against the standard oral tablet dosage form, and not the orodispersible dosage form. It is clear from the patent that Donepezil is a precursor to Donepezil hydrochloride but why it is listed at all, let alone against only one of the Eisai products, is a mystery that is likely being untangled in the ongoing litigation in the US (discussed later).

Equivalent patents in the last key patent family claim a composition comprising Donepezil and an organic acid and relate to the marketed formulation. All of the patents in this family were granted by the respective patent offices and will expire at the end of March 2019, however since the formulation of the Aricept® products does not contain an organic acid according to many sources this patent appears to offer no significant protection of the commercial product. This obviously raises the question over the purpose of it's listing in the Orange Book.

Two patent families specifically protecting the marketed ODT product have also been identified by the KPI. Both US equivalents (US7727548 and US7727552) were granted on 1st June 2010 and recently listed in the Orange Book. The term of US7727548 has been officially adjusted by 479 days and will expire on 23rd June 2022. Due to orodispersible tablet formulations in the prior art and the specific nature of these identified key patents, it is not thought the US patents will serve to prevent generic competitors from developing and launching their own orodispersible formulations.

According to the Marketing Authorisation Holders (Table 3), Teva and Mutual have obtained final FDA approval for the tablet and orodispersible tablet respectively, despite the fact that the molecule patent of Donepezil is still in force. The Teva final approval came upon expiry of the 30 month stay of approval of Teva's ANDA whilst litigation is ongoing. Should Teva have been tempted to launch 'at risk', Eisai blocked this opportunity by winning a preliminary injunction which orders Teva not to sell generic Aricept® as claimed in US4895841 until it's expiry in November 2010. Litigation surrounding the Aricept® product in the US as reported by the Litigation Alerts in Pipeline Selector is extensive and complex, full details of which are available in the full report.

Table 3: Marketing Authorisation Holders

Country Marketing Authorisation Holders

10 ARTG identified

2 PBS identified

CA 4 identified
GB 46 identified, 4 new, 0 updated
US 18 identified, 0 new, 0 updated

Many generic equivalents to both Aricept® dosage forms have been identified in the UK, suggesting that European markets will be flooded by generics as soon as the molecule patent expires February 2012. A similar situation looks likely in Australia in March 2013, with Synthon already waiting in the wings with an ARTG listed generic. Although no generic product has been identified as being authorised in Canada at the moment (presumably due to the late expiry of the molecule patent), a number of generic companies have filed an application for Notice of Compliance (NOC) for a generic equivalent to Aricept®. Accordingly, lawsuits have been filed asserting infringement of the relevant Canadian patents.

A review of the Patent Filing Trends for Donepezil, based on the comprehensive patent search report contained in the Pipeline Developer, reveals process patents account for more than a quarter of all patent families identified. This indicates that synthesising, or sourcing of non-infringing API to use in the formulation may be problematic. This is compounded by the number of patents covering the molecular form, which account for 15% of all applications filed in relation to Donepezil. The high numbers of molecular form patents create a significant barrier for generic companies who want to circumvent the polymorphic form patents listed in the KPI by producing a different polymorph. It is therefore in the best interests of any generic company wishing to develop generic versions of any Donepezil products to be fully informed of the existence of these patents and consider them with appropriate strategies.

Figure 1: Donepezil Patent Category Distribution

According to the Top Patent Applicants chart (Figure 2), Eisai tops the chart and has filed 25% of all patent applications relevant to Donepezil. This indicates the innovator's strong intention of protecting the marketed product, despite the fact that it's Orange Book listed patents are being challenged by several generic companies. Many other companies have filed relevant patent applications, and this is due to patents broadly claiming "anti-dementia/anti-Alzheimer's' treatments" or "acetylcholinesterase inhibitors", as well as a large amount of generic competition.

Figure 2: Donepezil Top Patent Applicants

In conclusion, it appears that Eisai has spent a reasonable amount of resources laying down patent barriers to prevent generic competition on its Aricept® product, considering the large number of patent applications filed. However, the scope and strength of protection of these patents does not appear significant enough to prevent generic competitors from entering the market beyond expiry of the patent protecting the molecule per se. Therefore, a surge in generic activity is expected in the all markets once the molecule patent (and any 180 day exclusivity period if applicable) expires. In Europe, the molecule patent will be in force for a further 15 months beyond the US equivalent due to variations in the patent term calculations. Despite this, the patent landscape around Donepezil is heavily populated with many risks, and it is advised that this is comprehensively assessed by interested generic companies to avoid costly litigation. Obviously, this would not be possible without first comprehensively identifying relevant patents from the over 50 million published patent documents worldwide, and keeping this information up to date.

Comprehensive data for patent families relating to Donepezil, based on professional patent searching, may be accessed by subscribing to the GenericsWeb Pipeline Developer report which include twelve monthly updates to keep you abreast of recently published patents and applications. GenericsWeb Pipeline Selector reports (Core and Extended) are available for any active ingredient upon request.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Mondaq Advice Centre (MACs)
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.